Answer
Plerixafor selectively and reversibly antagonises the CXCR4 chemokine receptor, preventing binding of stromal cell-derived factor-1α (SDF-1α), also known as CXCL12.
Sources for this answer
- Plerixafor Seacross 20 mgml solution for injectionSeacross Pharmaceuticals Ltd · emc · SmPC §5.1 Pharmacodynamic properties · Version 2Document updated
Sources checked